Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparing Magnetic Resonance Imaging/Spectroscopy Techniques

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001219
First received: November 3, 1999
Last updated: November 11, 2014
Last verified: July 2014

November 3, 1999
November 11, 2014
June 1987
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00001219 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparing Magnetic Resonance Imaging/Spectroscopy Techniques
Magnetic Resonance Imaging at 1.5 and 3.0 Tesla

Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) are diagnostic tests that allow researchers to look at different chemical properties of tissue. Magnetic resonance imaging and spectroscopy studies can be used to gather or evaluate information about various aspects of patient s bodies or to monitor changes in the biochemistry and physiology of patient s bodies.

Unlike other diagnostic techniques (CT scan and PET scan) MRI and MRS do not use ionizing radiation. Some studies have shown that MRI is more effective at distinguishing normal parts of the anatomy from abnormal anatomy, especially in the brain. MRI has become the diagnostic test of choice for evaluating patient with multiple sclerosis.

The purpose of this study is to evaluate normal volunteers and patients with a variety of diseases with magnetic resonance imaging. Researchers will attempt different magnetic resonance imaging methods and techniques as well as different levels of magnetic strength.

MRI is a constantly evolving imaging modality and MR. Pulse sequences are often modified to improve their performance. However, many of these changes have not yet been approved by the FDA and therefore, are not considered standard of care. Some of these sequences require the use of new types of imaging coils, which are also investigational. The major purpose of this protocol is to inform patients undergoing MR scans in the Clinical Center that they may undergo scans that are not FDA approved and to get the patient's consent for this. This is not a formal research study since specific disease entities and specific pulse sequences are not studied in a systematic way. Rather, the purpose is to give NIH patients access to gradual improvements in MR technology that would otherwise not be available to them. A secondary purpose is to inform patients about the risks of MRI and gadolinium chelates which are commonly employed in MRI.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Healthy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
99999999
Not Provided
Not Provided
  • INCLUSION CRITERIA:

All patients undergoing MRI in the Clinical Center.

Patients must be able to provide informed consents.

EXCLUSION CRITERIA:

No contraindications to MRI.

Inability to understand consent form or consent process and the absence of a suitable guardian.

Refusal to Participate.

Both
Not Provided
No
Contact: John A Butman, M.D. (301) 402-5827 jbutmana@cc.nih.gov
United States
 
NCT00001219
870091, 87-CC-0091
Not Provided
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Not Provided
Principal Investigator: John A Butman, M.D. National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP